PHVS
Pharvaris NV
NASDAQ · Healthcare · Biotechnology · NL
$29.77
+7.32%0
Insider buys (3m)
19
Insider sells (3m)
-$20.4M
Net value (3m)
-13.4%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 13, 2026 | Lu Peng · officer: President | F-InKind | 109 | $31 |
| Oct 13, 2026 | Lu Peng · officer: President | F-InKind | 117 | $31 |
| Sep 25, 2026 | Monges Viviane · director | M-Exempt | 11,969 | $8.05 |
| Sep 25, 2026 | Monges Viviane · director | Sale | 11,969 | $33 |
| Sep 24, 2026 | Lu Peng · officer: President | M-Exempt | 45,308 | $2.59 |
| Sep 24, 2026 | Schikan Johannes Gerardus Christiaan Petrus · director | Sale | 800 | $36 |
| Sep 24, 2026 | Schikan Johannes Gerardus Christiaan Petrus · director | M-Exempt | 800 | $20 |
| Sep 23, 2026 | Nassif David W. · officer: CFO / CLO | Sale | 6,000 | $36 |
| Sep 21, 2026 | Schikan Johannes Gerardus Christiaan Petrus · director | Sale | 200,000 | $35 |
| Sep 21, 2026 | Lu Peng · officer: President | M-Exempt | 86,692 | $2.59 |
| Sep 21, 2026 | Lu Peng · officer: President | M-Exempt | 13,308 | $2.59 |
| Sep 21, 2026 | Lu Peng · officer: President | M-Exempt | 100,000 | $2.59 |
| Sep 21, 2026 | Lu Peng · officer: President | Sale | 100,000 | $35 |
| Sep 21, 2026 | Modig Berndt · director, officer: Chief Executive Officer | M-Exempt | 300,000 | $35 |
| Sep 21, 2026 | Lesage Anne · officer: Chief Early Development | Sale | 20,000 | $38 |
| Sep 21, 2026 | Glassman Robert · director | Sale | 14,493 | $39 |
| Sep 21, 2026 | Glassman Robert · director | M-Exempt | 14,493 | $18 |
| Sep 21, 2026 | Bjork Elisabeth · director | Sale | 52,500 | $38 |
| Sep 21, 2026 | Bjork Elisabeth · director | M-Exempt | 17,500 | $18 |
| Sep 21, 2026 | Bjork Elisabeth · director | M-Exempt | 35,000 | $14 |
| Sep 17, 2026 | Abele Stefan Andreas · officer: Chief Technical Ops Officer | Sale | 45,000 | $38 |
| Sep 17, 2026 | Glassman Robert · director | M-Exempt | 8,667 | $22 |
| Sep 17, 2026 | Abele Stefan Andreas · officer: Chief Technical Ops Officer | Sale | 1,400 | $39 |
| Sep 17, 2026 | Abele Stefan Andreas · officer: Chief Technical Ops Officer | M-Exempt | 45,000 | $16 |
| Sep 17, 2026 | Glassman Robert · director | Sale | 8,667 | $38 |
| Sep 16, 2026 | Souverijns Wim · officer: Chief Commercial Officer | Sale | 6,090 | $39 |
| Sep 16, 2026 | Souverijns Wim · officer: Chief Commercial Officer | Sale | 20,000 | $39 |
| Sep 16, 2026 | Souverijns Wim · officer: Chief Commercial Officer | M-Exempt | 20,000 | $17 |
| Sep 15, 2026 | Modig Berndt · director, officer: Chief Executive Officer | Sale | 2,291 | $39 |
| Sep 15, 2026 | Lu Peng · officer: President | F-InKind | 117 | $38 |
Institutional positioning
13F filings over the trailing two quarters
New 34Increased 82Reduced 69Sold out 11
| Filer | Action | Shares | Filed |
|---|---|---|---|
| GENERAL ATLANTIC, L.P. | Unchanged | 8,031,252 | May 15, 2026 |
| FMR LLC | Increased | 6,565,272 | Aug 13, 2026 |
| GENERAL ATLANTIC, L.P. | Reduced | 6,550,757 | Aug 14, 2026 |
| FMR LLC | Reduced | 6,284,472 | May 15, 2026 |
| Foresite Capital Management IV, LLC | Unchanged | 4,778,581 | Aug 14, 2026 |
| FORESITE CAPITAL MANAGEMENT IV, LLC | Unchanged | 4,778,581 | May 15, 2026 |
| venBio Partners LLC | Increased | 4,643,430 | Aug 14, 2026 |
| VENBIO PARTNERS LLC | Unchanged | 4,639,304 | May 15, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 3,653,310 | May 15, 2026 |
| VIKING GLOBAL INVESTORS LP | Unchanged | 3,653,310 | Aug 14, 2026 |
| EQT Fund Management S.a r.l. | Unchanged | 3,424,609 | Aug 13, 2026 |
| EQT FUND MANAGEMENT S.A R.L. | Unchanged | 3,424,609 | May 14, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | Increased | 3,376,042 | Aug 14, 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Unchanged | 3,126,042 | May 15, 2026 |
| Bain Capital Life Sciences Investors, LLC | Unchanged | 2,675,509 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 13, 2026